Truqap Use In Pregnancy & Lactation

Contraception in males and females: Women of childbearing potential should be advised to avoid becoming pregnant while receiving TRUQAP. A pregnancy test should be performed on women of childbearing potential prior to initiating treatment, and verified as negative prior to initiating treatment, and re-testing considered throughout treatment.
Patients should be advised to use effective contraception during treatment with TRUQAP and for the following periods after completion of treatment with TRUQAP: at least 4 weeks for females and 16 weeks for males.
Pregnancy: There are no data from the use of TRUQAP in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Therefore, TRUQAP is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding: It is not known whether capivasertib or its metabolites are excreted in human milk. Exposure to capivasertib was confirmed in suckling rat pups which may indicate the excretion of capivasertib in milk. A risk to the suckling child cannot be excluded (see Pharmacology: Toxicology: Preclinical safety data under Actions). Breast-feeding should be discontinued during treatment with TRUQAP.
Fertility: There are no clinical data on fertility. In animal studies, capivasertib resulted in tubular degeneration in male reproductive organs in mice, rats and dogs but had no effects on fertility in male rats. The effect on female fertility in rats has not been studied (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Refer to Use in Pregnancy & Lactation of the prescribing information for fulvestrant.